Study of XL820 in Adults With Solid Tumors

Exelixis

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: XL820

Study type: Interventional

Funder types: Industry

Identifiers

NCT00129571

XL820-001

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced solid tumor
• Cancer for which standard therapies do not exist or are no longer effective
• Life expectancy of > 3 months
• Adequate bone marrow, liver, and kidney function
• Willing to use accepted method of contraception during the course of the study
• Negative pregnancy test (females)
• Written informed consent

Exclusion criteria

• Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
• Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
• Investigational drug within 30 days of the start of treatment
• Subjects with known brain metastasis
• Uncontrolled medical disorder such as infection or cardiovascular disease
• Subjects known to be HIV positive
• Pregnant or breastfeeding women